Ramesh Radhakrishnan
Partner & Managing Director @ Artiman Ventures
San Francisco, United States
Ramesh Radhakrishnan is a seed investor at Artiman Ventures in San Francisco focused on Machine Learning and Artificial Intelligence. Ramesh Radhakrishnan is the Partner & Managing Director at Artiman Ventures. Additionally, Ramesh Radhakrishnan has had 1 past job as the VP of Engineering at FireEye.Ramesh has been a member of the founding entrepreneurial team in three startups. He has over 20 years of operational and business experience in the high technology industry,including networking, security and wireless companies. Prior to joining Artiman Capital India, Ramesh was the VP of Engineering at FireEye, a network security company that uses virtualization technology to detect and combat the menace of malware, botnets and crimeware. Prior to that, Ramesh led the systems and software development team at Airgo Networks. Airgo pioneered and invented the 802.11n MIMO OFDM wireless LAN standards and was acquired by Qualcomm in 2005. Prior to Airgo, Ramesh was the Director of the Wireless Access Business Unit at Cisco Systems. This business unit was the result of the acquisition of Clarity Wireless, a startup company where Ramesh led the engineering team that pioneered and created the wireless last mile standard which is WiMax today. Prior to Clarity Wireless, Ramesh was a founding member at ZeitNet, acquired by Cabletron in 1996, where he led the engineering team which made high speed LAN products. Before this, Ramesh was an engineering manager at Adaptive Corporation that brought ATM technology to the LAN. Adaptive was acquired by NET in 1994. Ramesh started his career as a software engineer at Hewlett Packard's Network Division in Cupertino.Ramesh holds two patents in the area of networking protocol technologies.Ramesh holds a B.E. from the Indian Institute of Technology (IIT), Chennai, and an M.E. in Systems Engineering from the University of Virginia, Charlottesville.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ramesh Radhakrishnan invests in
Stages Ramesh Radhakrishnan invests in
Countries Ramesh Radhakrishnan invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1M–$6.5M
Investment Focus
Industry
- Machine Learning 2 (50%)
- Artificial Intelligence 2 (50%)
- Apps 1 (25%)
- Medical 1 (25%)
- Computer 1 (25%)
Stage
- Seed 3 (75%)
- Series A 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| QpiAI vertically integrates quantum computing and AI for solutions in manufacturing, industrial, transportation, finance, pharmaceuticals, and materials with diverse software platforms and products and provides impactful advances to generative AI and various industry verticals. | $6.5M / Seed / Jun 21, 2024 | ||
| SmarterBiz is an AI-powered customer experience platform that enables remote management of customer journeys and agent life cycles. SmarterBiz has helped several enterprises, including unicorns build scalable, flexible, and hyper-local customer experience, cost-effectively. | $1.1M / Seed / Aug 20, 2020 | ||
| OncoStem Diagnostics Private Limited is Mauritius incorporation with subsidiaries in India and US. It is founded by Cell Biology veteran with significant experience in US, Singapore and India in cancer biology & cancer drug discovery. Of the many challenges in medicine, none has experienced more hard-fought progress than the treatment andcure of cancer. ‘Recurrence’ of cancer is still the single most feared feature of cancer by the patients and oncologists since it is often the cause of morbidity and mortality associated with the disease. Risk of recurrence can vary from cancer to cancer. Accurate prediction of ‘risk of recurrence’ is one of the most important features required to plan optimum and effective treatment. At present, most cancer patients get surgery plus chemotherapy and radiation therapy to prevent cancer recurrence. These treatments are very generic, have severe side effects which reduce quality of life of patients. Finding targeted drugs (e.g. Gleevec, Herceptin) to prevent recurrence is the need of the hour. OncoStem is focussing on these two main issues viz predicting risk of recurrence and developing new targeted drugs to alleviate pain of cancer patients through improved diagnostics. OncoStem is developing novel diagnostic tests which will predict ‘risk of recurrence’ and prescribe targeted drugs to prevent cancer recurrence. Their first focus is breast cancer. | $6M / Series A / Sep 06, 2017 | ||
| OncoStem Diagnostics Private Limited is Mauritius incorporation with subsidiaries in India and US. It is founded by Cell Biology veteran with significant experience in US, Singapore and India in cancer biology & cancer drug discovery. Of the many challenges in medicine, none has experienced more hard-fought progress than the treatment andcure of cancer. ‘Recurrence’ of cancer is still the single most feared feature of cancer by the patients and oncologists since it is often the cause of morbidity and mortality associated with the disease. Risk of recurrence can vary from cancer to cancer. Accurate prediction of ‘risk of recurrence’ is one of the most important features required to plan optimum and effective treatment. At present, most cancer patients get surgery plus chemotherapy and radiation therapy to prevent cancer recurrence. These treatments are very generic, have severe side effects which reduce quality of life of patients. Finding targeted drugs (e.g. Gleevec, Herceptin) to prevent recurrence is the need of the hour. OncoStem is focussing on these two main issues viz predicting risk of recurrence and developing new targeted drugs to alleviate pain of cancer patients through improved diagnostics. OncoStem is developing novel diagnostic tests which will predict ‘risk of recurrence’ and prescribe targeted drugs to prevent cancer recurrence. Their first focus is breast cancer. | $1M / Seed / Jul 01, 2011 |
Co-Investors
About Artiman Ventures
Artiman is an early-stage venture fund that seeks to invest in entrepreneurs that have the potential to disrupt multi-billion markets. The firm was established in 2000 and is headquartered in Palo Alto, California, United States.
Artiman Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ajit Singh
Partner
|
|||
Amit Shah
Founder & Partner
|
|||
|
Ramesh Radhakrishnan
Partner & Managing Director
|
|||
Brian Wilcove
Partner
|
|||
Mahmood Panjwani
Entrepreneur in Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Ramesh Radhakrishnan invest in?
Ramesh Radhakrishnan invests primarily in Machine Learning, Artificial Intelligence and Apps startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ramesh Radhakrishnan's check size?
Ramesh Radhakrishnan typically joins rounds of $1M–$6.5M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ramesh Radhakrishnan participates in.
How do I contact Ramesh Radhakrishnan?
Public channels for Ramesh Radhakrishnan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ramesh Radhakrishnan last invest?
The most recent investment recorded for Ramesh Radhakrishnan closed in Jun 2024. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
